Healthcare spending to lift Duopharma

Public-sector segment’s revenue contribution for Duopharma was 50% and 44% in FY24 and FY23, respectively.

PETALING JAYA: TA Research expects Duopharma Biotech Bhd’s revenue from its public-sector segment to increase to 53% this year (FY25) following a recent contract win to supply additional products to the government via Pharmaniaga Logistics Sdn Bhd.

Public-sector segment’s revenue contribution for Duopharma was 50% and 44% in FY24 and FY23, respectively.